Isotopic Labeling of the Tyrosine Kinase Inhibitor Binimetinib with Fluorine-18 and Preclinical Evaluation
The Ras-Raf-MEK-ERK signaling pathway is involved in numerous cancers. Monitoring its overactivation by PET imaging remains challenging, yet it holds significant potential for personalized diagnostics. Here, we report the fluorine-18 isotopic radiolabeling of binimetinib, an FDA-approved specific allosteric MEK1/2 inhibitor, for the treatment of BRAF-positive melanoma. The inherent structure of binimetinib makes its radiolabeling a strong challenge, addressed by evaluating seven precursors using a simplified model compound. A fully automated, four-step, one-pot radiosynthesis afforded [18F]binimetinib with a 9 ± 5% radiochemical yield after 100 min with >95% radiochemical purity. In vitro evaluation of [18F]binimetinib demonstrated specific uptake in H358 cells with activated Ras-Raf-MEK-ERK. PET imaging of an H358 xenograft mouse model revealed promising tumor uptake at 4 h post-injection with 1.96 ± 0.51 % ID.cm−3 in the tumor. This study provides insight into the in vivo pharmacokinetic profile derived from PET imaging of [18F]binimetinib and its potential for investigating MEK target availability in tumors.
Authors
- Simon Specklin (ORCID: https://orcid.org/0000-0002-2804-3761)
- Bertrand Kühnast (ORCID: https://orcid.org/0000-0002-5035-4072)
- Charles Truillet (ORCID: https://orcid.org/0000-0002-1782-5418)
- Caroline Denis
- Rémi Pelletier (ORCID: https://orcid.org/0000-0002-1065-1398)
- Benoit Jégo
Institutions
- Université Paris-Saclay (FR)
- Institut des Sciences des Plantes de Paris Saclay (FR)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c02001
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00